Treatment of Colon Cancer with Radiolabeled Cea Antibody

Buchsbaum, Donald J.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Research Project (R01)
• Project #: 2R01CA044173-04A1
• Application #: 3186760
• Study Section: Experimental Therapeutics Subcommittee 1 (ET)
• Project Start: 1987-01-01
• Project End: 1990-09-30
• Budget Start: 1990-07-01
• Budget End: 1990-09-30
• Support Year: 4
• Fiscal Year: 1990

Institution

• Name: University of Michigan Ann Arbor
• Type: Schools of Medicine
• DUNS #: 791277940
• City: Ann Arbor
• State: MI
• Country: United States
• Zip Code: 48109

Publications

Buchsbaum, D J; Khazaeli, M B; Mayo, M S et al. (1999) Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model. Clin Cancer Res 5:3153s-3159s

Roberson, P L; Dudek, S; Buchsbaum, D J (1997) Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model. Cancer 80:2567-75

Roberson, P L; Buchsbaum, D J (1995) Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model. Cancer Res 55:5811s-5816s

Roberson, P L; Heidorn, D B; Kessler, M L et al. (1994) Three-dimensional reconstruction of monoclonal antibody uptake in tumor and calculation of beta dose-rate nonuniformity. Cancer 73:912-8

Roberson, P L; Buchsbaum, D J; Heidorn, D B et al. (1992) Three-dimensional tumor dosimetry for radioimmunotherapy using serial autoradiography. Int J Radiat Oncol Biol Phys 24:329-34

Werner, B L (1991) Dose distributions in regions containing beta sources: irregularly shaped source distributions in homogeneous media. Med Phys 18:1192-4

Werner, B L; Rahman, M; Salk, W N et al. (1991) Dose distributions in regions containing beta sources: uniform spherical source regions in homogeneous media. Med Phys 18:1181-91

Buchsbaum, D J; Lawrence, T S (1990) New trends in the use of radioimmunoconjugates for the therapy of cancer. Targeted Diagn Ther 3:215-55